Skip to content
Search

Latest Stories

PSNC disappointed as CPCF annual review ends without funding boost

The Pharmaceutical Services Negotiating Committee (PSNC) has expressed disappointment as the government continued to refuse to “a much-needed broader funding uplift” for the community pharmacies in England.

This follows conclusion of the first Annual Review of the progress of the five-year Community Pharmacy Contractual Framework (CPCF) deal by PSNC, the Department of Health and Social Care (DHSC) and NHS England & NHS Improvement (NHSE&I).


“We remain deeply frustrated by government’s refusal to agree a much-needed broader funding uplift for the sector, but we are determined to continue to look for better ways forward for the sector throughout 2022 and beyond,” said Bharat Patel, PSNC vice-chair, negotiating team member and an independent contractor.

Patel noted that despite some important wins such as recognition of key challenges faced by pharmacies, the commitment to consider these as part of our Year 4 negotiations, and agreement to take forward work on service fee and other regulatory changes, the PSNC is disappointed that the review did not lead to “immediate and tangible outcomes and improvements for contractors.”

The negotiator had put forward data and analysis showing the capacity and cost constraints faced by pharmacies.

Mike Dent, PSNC director of Pharmacy Funding, said: “Our data also provides useful evidence to support ongoing discussions about the extraordinary performance and value of pharmacies”.

“PSNC is now working to build on the outputs of the review in the upcoming Year 4 negotiations: we will be gathering and analysing more data to support our discussions, as well as continuing to highlight the pressures on the sector, and exploring ways to bid again for additional funding over the course of this year.”

Tricia Kennerley, PSNC negotiating team member and VP, director International Public Affairs at Walgreens Boots Alliance, said that situation for contractors continues to worsen.

She added that PSNC has clearly stated “the immense pressures the sector is facing”, which is important ahead of “another critical round of discussions for the sector, with many contractors simply unable to take on any further services without additional funding, support and access to the right staff.”

Reacting to the review outcome, the National Pharmacy Association chief executive Mark Lyonette said: “It appears this annual contract review has rubber-stamped another year of cuts for pharmacies across England.

“This is an insult to pharmacy teams, who have worked relentlessly hard to help keep the country on its feet during the Covid pandemic."

He added that high costs, increased public demand for pharmacy support have increased pressures and demotivated many staff.

“Instead of moving forwards into new clinical roles, which the NHS and DHSC say they want, pharmacies could now slip back, focus narrowly on dispensing and reduce access to care – the very opposite of the aspirations stated in the NHS Plan.

“Governments, NHS and negotiators elsewhere in the UK are working to agreed visions and decently funded strategies. England should follow suit and jettison the nonsense that great services can be provided on a shorter and shorter shoestring.”

Meanwhile, PSNC stated that all parties have agreed to:

  • Recognise the capacity constraints within the sector in the upcoming Year 4 negotiations;
  • Explore the scale and impact of the more complex consultations now taking place in community pharmacy – the Pharmacy Advice Audit begins this process;
  • Continue and conclude discussions on services fee setting principles; and
  • Consider measures for assessing capacity within community pharmacies.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less